

PUBLIC NOTICE TO CUSTOMERS AND DISTRIBUTORS

Regarding Sale Price of Bortezomib 2 mg, 2.5 mg and 3.5 mg

Jodas Expoim Private Limited hereby informs all its customers, distributors, stockists, hospitals, institutions and other trade partners that the prices of **Bortezomib 2 mg, Bortezomib 2.5 mg and Bortezomib 3.5 mg** are subject to the applicable price controls and ceiling prices notified/fixed by the **National Pharmaceutical Pricing Authority (NPPA), Government of India**.

Accordingly, all distributors, stockists and other trade partners are **strictly required to ensure that the aforesaid products are not sold or supplied at a price higher than the applicable price fixed/notified by NPPA**, including applicable statutory taxes, wherever applicable.

No distributor, stockist or other trade partner is authorised by Jodas Expoim Private Limited to charge any price in excess of the applicable NPPA-approved ceiling price.

Customers and institutions are therefore requested to verify the price charged to them and, **if any distributor, stockist or other trade partner is found to be charging a price higher than the applicable NPPA-fixed price**, to immediately bring the matter to the attention of Jodas Expoim Private Limited, along with details of the product, batch number, invoice/bill and the price charged.

Jodas Expoim Private Limited will examine such complaints and take appropriate action, as may be warranted, in accordance with applicable law and its commercial arrangements with the concerned distributor/stockist.

This notice is issued in the interest of **price transparency, patient protection and compliance with applicable Government of India pricing regulations.**

For Jodas Expoim Private Limited

Dr. Jyoti Loomba
Managing Director



Satyendra Kumar Singh
Managing Director

Date: 20th August 2026

Place: Hyderabad